Workflow
Prothena(PRTA) - 2024 Q4 - Earnings Call Presentation

Financial Performance & Guidance - Prothena's net cash used in operating and investing activities for FY 2024 was $150.3 million, aligning with the guidance of $148 - $160 million[54] - The company's net loss for FY 2024 was $122.3 million, including $46 million in non-cash share-based compensation expense, which was in line with the guidance of $120 - $135 million[54, 55] - Prothena's year-end cash balance for 2024 was $472.2 million, consistent with the guidance of $468 million[54] - For FY 2025, Prothena anticipates net cash usage in operating and investing activities between $168 million and $175 million[56] - The projected net loss for FY 2025 is between $197 million and $205 million, which includes an estimated $41 million in non-cash share-based compensation expense[56, 57] - The company forecasts a year-end cash balance of $301 million for 2025 (midpoint)[56] Pipeline Development - Topline results from the Phase 3 AFFIRM-AL trial of birtamimab in AL amyloidosis are expected in Q2 2025[10, 60] - Multiple data readouts from the Phase 1 ASCENT clinical trials of PRX012 for Alzheimer's disease are anticipated starting in mid-2025 and continuing throughout the year[11, 60, 62] - Completion and results of the ongoing Phase 2 trial of coramitug (PRX004) in ATTR-CM are expected in 2025[14, 61] - Roche will determine the next steps for prasinezumab in Parkinson's disease in 2025[14, 61] - The Phase 2 trial of BMS-986446 (PRX005) in Alzheimer's disease is expected to be completed in 2027[14, 61] - The Phase 1 trial of PRX019 in neurodegeneration is expected to be completed in 2026[14, 61] Birtamimab Market Opportunity - Birtamimab has multi-billion dollar global market potential in AL Amyloidosis[10, 48] - Approximately 5,000 patients in the US and over 5,000 in the EU are Mayo Stage IV patients, representing a target population for Birtamimab[42]